ArticleCureus2026
Sequential Transformation of Polycythemia Vera to Myelofibrosis and KMT2A-Rearranged Acute Myeloid Leukemia Treated With Revumenib: A Rare Case of Clonal Evolution.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transformation of polycythemia vera (PV) into post-polycythemic myelofibrosis (MF) and subsequently acute myeloid leukemia (AML) represents one of the most aggressive trajectories among myeloproliferative neoplasms (MPNs). Post-MPN AML carries a median survival of approximately six months, particularly among older adults with adverse cytogenetics. We report the case of a 73-year-old man with JAK2-positive PV diagnosed in 2020 who progressed to MF in 2024 and developed AML later that year. Cytogenetic analysis revealed a KMT2A (11q23) rearrangement with KMT2A::ELL fusion, a finding rarely described in secondary AML arising from MPNs. Due to advanced age, transfusion dependence, and significant cardiovascular comorbidities, the patient was not a candidate for intensive chemotherapy or hematopoietic stem cell transplantation. He was initially treated with azacitidine and venetoclax but demonstrated disease progression. In the setting of a KMT2A::ELL fusion, therapy was transitioned to the menin inhibitor revumenib, resulting in short-term clinical stability and tolerability under continued supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.